Drug - Intranasal Corticosteroid Class
Therapeutic area - Respiratory/Asthma/COPD
Beconase AQ PA
Recipient must try and fail 2 of the preferred agents after a documented trial of at least two weeks of continued, daily use of the agent.
Failure is defined as:
Allergic rhinitis or non-allergic vasomotor rhinitis
For any other diagnoses, (for example sinusitis, rhinosinusitis) the patient falls out of FDA approved prescribing guidelines. PA’s will not be granted.
Expected side effects of any agent in the class are not considered failure and may include: stinging, burning, dryness, sneezing, epistaxis, bad taste, and Candida overgrowth. Counseling on proper drug administration is strongly encouraged.
All of the preferred agents have been studied specifically for growth markers in children and have been found to not affect growth rate.
MHCP Provider Call Center 651-431-2700 or 800-366-5411